Mantle cell lymphoma · 4 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Bortezomib and Rituximab (VR) Variant #06 | — | R 64 235 | 35d | ~12.8 mo | — | ~12 | ~R 770 814 PFS proxy · indirect | 1 |
Lenalidomide monotherapy N/A - secondary systemic drug | — | R 6 361 | 90d | — | — | — | — | 1 |
Rituximab monotherapy N/A - secondary systemic drug | — | R 52 | 180d | — | — | — | — | 2 |
Observation Partial | — | — | — | — | — | — | — | 1 |
4 of 4 regimens shown